The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.
The acute respiratory distress syndrome (ARDS) is a syndrome of severe acute lung inflammation and hypoxemic respiratory failure with an incidence of 180,000 cases annually in the U.S.Despite decades of research and recent advances in lung protective ventilator strategies, morbidity and mortality remain unacceptably high. Furthermore, no specific effective pharmacologic therapies currently exist. The lack of specific effective therapies for sepsis-related ARDS indicates a need for new treatments that target novel pathways. Carbon monoxide (CO) represents a novel therapeutic modality in ARDS based on data obtained in experimental models of ARDS and sepsis over the past decade. CO has been shown to be protective in experimental models of Acute Lung Injury (ALI), including hyperoxia and endotoxin exposure, bleomycin, ischemia/reperfusion, and ventilator-induced lung injury (VILI). At low doses, CO has been shown to confer tissue protective effects in these ALI models. In addition, CO has been shown to decrease inflammation, enhance phagocytosis, and improve mortality in models of sepsis including endotoxemia, hemorrhagic shock, and cecal ligation and puncture (CLP). CO has also been shown to have beneficial therapeutic effects in pre-clinical models of disease including pulmonary hypertension, vascular injury, and transplantation. Furthermore, multiple human studies have demonstrated that experimental administration of several different concentrations of CO is well tolerated and that low dose inhaled CO can be safely administered to subjects in a controlled research environment. The purpose of this study is to assess the safety of inhaled CO therapy in mechanically ventilated patients with sepsis-induced ARDS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
Inhaled Medical Air for up to 90 minutes daily for 5 days
Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Weill Cornell Medical College/NewYork-Presbyterian
New York, New York, United States
Duke Univesity Hospital
Durham, North Carolina, United States
Number of administration associated adverse events.
1. Acute myocardial infarction (MI) within 48 hours of study drug administration 2. Acute cerebrovascular accident (CVA) within 48 hours of study drug administration 3. New onset atrial or ventricular arrhythmia requiring direct current (DC) cardioversion within 48 hours of study drug administration 4. Increased oxygenation requirements defined as: an increase in fraction of inspired oxygen (FiO2) of greater than or equal to 0.2 AND increase in PEEP greater than or equal to 5 cm of water (H2O) within 6 hours of study drug administration 5. Increase in any protocol-specified measurement of carboxyhemoglobin (COHb) greater than or equal to 10% 6. Increase in lactate by greater than or equal to 2 mmol/L within 6 hours of study drug administration
Time frame: 60 Days if remains in the ICU
Incidence of serious adverse events (SAEs).
An SAE is any event that is fatal or immediately life threatening, is permanently disabling, or severely incapacitating, or requires or prolongs inpatient hospitalization. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: 60 Days if remains in the ICU
Comparison between the calculated carboxyhemoglobin (COHb) level at 90 minutes using the Coburn-Forster-Kane (CFK) equation and measured COHb level at 90 minutes
The Coburn-Forster-Kane (CFK) equation will be used to calculate the estimated COHb level at 90 minutes for Cohorts 1 and 2.
Time frame: 5 days
Mean daily Sequential Organ Failure Assessment (SOFA) score
Organ failure will be assessed using the SOFA score. SOFA scores will be assessed daily on days 1-5, and day 7, as the SOFA score has been shown to be a reliable prognostic indicator of outcomes in critically ill patients.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Inhaled Medical Air for up to 90 minutes daily for 5 days
Time frame: 7 days
Partial pressure of arterial oxygen (PaO2)/FiO2 ratio
PaO2/FiO2 will be measured daily on days 1-5 if a subject remains mechanically ventilated.
Time frame: 5 days
Oxygenation index (OI)
The OI will be measured daily on days 1-5 if a subject remains mechanically ventilated.
Time frame: 5 days
Lung injury score (LIS)
The LIS is a composite 4-point scoring system including the PaO2/FiO2, PEEP, quasi-static respiratory compliance, and the extent of infiltrates on the chest X-ray. Previous randomized clinical trials in ARDS have shown that a decreased LIS correlates with improvement in lung physiology as well as important clinical outcomes including mortality and ventilator-free days (VFDs).
Time frame: 7 Days
Vasopressor-free days
Ventilator-free days will be assessed on day 28.
Time frame: 28 days
Ventilator-free days (VFDs)
Ventilator-free days to day 28 are defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFDs will be counted from the end of the last period of assisted breathing to day 28.
Time frame: 28 days
ICU-free days
ICU-free days will be assessed on day 28.
Time frame: 28 days
Hospital-free days
Hospital-free days will be assessed on day 60.
Time frame: 60 days